EFFICACY AND SAFETY OF UPADACITINIB IN TNFI INADEQUATE RESPONDERS WITH RHEUMATOID ARTHRITIS FROM THREE PHASE 3 CLINICAL TRIALS

被引：0

作者：

Fleischmann, Roy ^{[1
]}

Bessette, Louis ^{[2
]}

Hall, Stephen ^{[3
,4
]}

Sparks, Jeffrey ^{[5
]}

Jain, Manish ^{[6
]}

Kakehasi, Adriana ^{[7
]}

Song, Yanna ^{[8
]}

Meerwein, Sebastian ^{[8
]}

DeMasi, Ryan ^{[8
]}

Suboticki, Jessica ^{[8
]}

Rubbert-Roth, Andrea ^{[9
]}

机构：

[1] Metroplex Clin Res Ctr, Rheumatol, Dallas, TX USA

[2] Laval Univ, Div Rheumatol, Dept Med, Quebec City, PQ, Canada

[3] Monash Univ, Rheumatol, Melbourne, Australia

[4] Emeritus Res, Melbourne, Australia

[5] Brigham & Womens Hosp, Div Rheumatol Inflammat & Immun, Boston, MA USA

[6] Great Lakes Clin Trials, Rheumatol, Chicago, IL USA

[7] Univ Fed Minas Gerais, Hosp Clin, Rheumatol, Belo Horizonte, Brazil

[8] AbbVie Inc, Immunol, Chicago, IL USA

[9] Cantonal Clin St Gallen, Div Rheumatol, St Gallen, Switzerland

来源：

RHEUMATOLOGY | 2023年 / 62卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P135

引用

页数：2

共 50 条

[41] Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials
Ben Klünder
Mohamed-Eslam F. Mohamed
Ahmed A. Othman
Clinical Pharmacokinetics, 2018, 57 : 977 - 988
[42] Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials
Kluender, Ben
Mohamed, Mohamed-Eslam F.
Othman, Ahmed A.
CLINICAL PHARMACOKINETICS, 2018, 57 (08) : 977 - 988
[43] Efficacy and Safety of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs: A United States Subpopulation Analysis from Two Phase 3 Trials
Wells, Alvin F.
Greenwald, Maria
Bradley, John D.
Alam, Jahangir
Arora, Vipin K.
Kartman, Cynthia E.
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[44] Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic DMARDs: Results Through 5 Years From the SELECT-BEYOND Study
Fleischmann, R.
Meerwein, S.
Charles-Schoeman, C.
Combe, B.
Hall, S.
Khan, N.
Carter, K.
Camp, H.
Rubbert-Roth, A.
SWISS MEDICAL WEEKLY, 2023, 153 : 26S - 26S
[45] Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic DMARDs: Results Through 5 Years from the SELECT-BEYOND Study
Fleischmann, Roy
Meerwein, Sebastian
Charles-Schoeman, Christina
Combe, Bernard
Hall, Stephen
Khan, Nasser
Carter, Kyle
Camp, Heidi
Rubbert-Roth, Andrea
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 567 - 570
[46] Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study
Fleischmann, Roy
Meerwein, Sebastian
Charles-Schoeman, Christina
Combe, Bernard
Hall, Stephen
Khan, Nasser
Carter, Kyle M.
Camp, Heidi S.
Rubbert-Roth, Andrea
RMD OPEN, 2024, 10 (03):
[47] LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO CSDMARDS: RESULTS AT 60 WEEKS FROM THE SELECT-NEXT STUDY
Burmester, Gerd Ruediger
van den Bosch, Filip
Bessette, Louis
Kivitz, Alan
Li Yihan
Friedman, Alan
Pangan, Aileen
Camp, Heidi
Kremer, Joel
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 735 - 736
[48] Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic DMARDs: Results Through 5 Years from the SELECT-NEXT Study
Burmester, Gerd
Van den Bosch, Filip
Tesser, John
Shmagel, Anna K.
Duan, Yuanyuan
Khan, Nasser
Camp, Heidi
Kivitz, Alan
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 570 - 573
[49] Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic DMARDs: Results Through 5 Years From the SELECT-NEXT Study
Burmester, G.
van den Bosch, F.
Tesser, J.
Shmagel, A.
Duan, Y.
Khan, N.
Camp, H.
Kivitz, A.
SWISS MEDICAL WEEKLY, 2023, 153 : 26S - 26S
[50] Randomized Clinical Trials on the Efficacy and Safety of Tocilizumab in Subjects with Rheumatoid Arthritis: A Systematic Review
Sadeq, Adel
Elnour, Asim Ahmed
Ramadan, Azza
Kidir, Israa Yousif
Don, Judit
Al Amoodi, Abdulla
Al Mazrouei, Nadia
Baraka, Mohamed A.
Farah, Farah Hamad
Alkaabi, Maisoun
CURRENT REVIEWS IN CLINICAL AND EXPERIMENTAL PHARMACOLOGY, 2023, 18 (01) : 64 - 87

← 1 2 3 4 5 →